Contact Residues Protooncogene by Alterations of MHC Immunodominant Epitope of the Her-2/neu Improved Immunogenicity of an
暂无分享,去创建一个
J. Sidney | A. Sette | R. Kiessling | S. Vertuani | S. Southwood | J. Fikes | J. Levitskaya | G. Ishioka | E. Keogh | J. Lindencrona
[1] P. Musiani,et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. , 2003, Cancer research.
[2] H. Fujii,et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] J. Murray,et al. Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex1 , 2002, The Journal of Immunology.
[4] Thierry Boon,et al. Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.
[5] M. Ziol,et al. Amino acid modifications in the wild type sequence p53 232–240 overcome the poor immunogenicity of this self tumour epitope , 2002, Journal of peptide science : an official publication of the European Peptide Society.
[6] M. Cheever,et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] G. Forni,et al. Prophylactic cancer vaccines. , 2002, Current opinion in immunology.
[8] A Choudhury,et al. Cellular immunity to the Her-2/neu protooncogene. , 2002, Advances in cancer research.
[9] J. Schlom,et al. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] T. Eberlein,et al. Modification of the HER2/NEU‐derived tumor antigen GP2 improves induction of GP2‐reactive cytotoxic T lymphocytes , 2001, International journal of cancer.
[11] R. Steinman,et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.
[12] Alessandro Sette,et al. Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity1 , 2001, The Journal of Immunology.
[13] F. Fallarino,et al. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] K. Knutson,et al. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.
[15] Steven A. Rosenberg,et al. Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution , 2001, Journal of immunotherapy.
[16] Piero Musiani,et al. DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.
[17] L. Kanz,et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.
[18] E. Jaffee,et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.
[19] Sylvia Janetzki,et al. Evaluation of CD8+ T‐cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide , 2000, International journal of cancer.
[20] J. Schlom,et al. Agonist peptide from a cytotoxic t‐lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1‐type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide , 2000, International journal of cancer.
[21] P. Romero,et al. Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue , 2000, The Journal of Immunology.
[22] Shuqin Yan,et al. Poor Binding of a HER-2/neu Epitope (GP2) to HLA-A2.1 Is due to a Lack of Interactions with the Center of the Peptide* , 1999, The Journal of Biological Chemistry.
[23] A Sette,et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. , 1999, Journal of immunology.
[24] Parkhurst,et al. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. , 1999, Journal of immunology.
[25] G. Parmiani,et al. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. , 1999, Cancer research.
[26] B. Moss,et al. gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.
[27] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[28] J. Altman,et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.
[29] A. Sette,et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.
[30] J. Sidney,et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. , 1997, Journal of immunology.
[31] J. Sidney,et al. The HLA-A*0207 peptide binding repertoire is limited to a subset of the A*0201 repertoire. , 1997, Human immunology.
[32] A Sette,et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.
[33] J. Wharton,et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.
[34] A. Vitiello,et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.
[35] J. Wharton,et al. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. , 1994, Cellular immunology.
[36] J. Sidney,et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.
[37] H. Grey,et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Sidney,et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.
[39] A. Vitiello,et al. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.
[40] C. Cordon-Cardo,et al. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.